Chakraborti CK. Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity. World J Diabetes 2015; 6(15): 1296-1308 [PMID: 26557957 DOI: 10.4239/wjd.v6.i15.1296]
Corresponding Author of This Article
Dr. Chandra Kanti Chakraborti, Professor, Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela 769015, Odisha, India. chandrakanti_12@rediffmail.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Nov 10, 2015; 6(15): 1296-1308 Published online Nov 10, 2015. doi: 10.4239/wjd.v6.i15.1296
Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity
Chandra Kanti Chakraborti
Chandra Kanti Chakraborti, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela 769015, Odisha, India
Author contributions: Chakraborti CK solely contributed to this manuscript.
Conflict-of-interest statement: The author has no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Chandra Kanti Chakraborti, Professor, Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela 769015, Odisha, India. chandrakanti_12@rediffmail.com
Telephone: +91-0977-6145092 Fax: +91-0661-2480752
Received: July 9, 2015 Peer-review started: July 14, 2015 First decision: August 25, 2015 Revised: September 14, 2015 Accepted: October 23, 2015 Article in press: October 27, 2015 Published online: November 10, 2015 Processing time: 124 Days and 15.4 Hours
Core Tip
Core tip: The objective of this article is to establish the connection of obesity with that of insulin resistance (IR) and type 2 diabetes mellitus (T2DM) by analyzing the recent developments in this field. The factors linking the three have been found to be some adipocytokines as well as certain other factors not of adipocyte origin. Of these, adiponectin appears to play the most beneficial role (so also leptin, peroxisome proliferator-activated receptors, apelin, etc.), while others (tumour necrosis factor-alpha, interleukin-6, resistin, retinol binding protein-4, dipeptidyl peptidase-4, plasminogen activator inhibitor-1, visfatin, free fatty acid, angiotensin II and toll-like receptors) are harmful. Agonists and antagonists of these factors may be designed to fight against obesity, thereby achieving protection for IR and T2DM.
